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The well-recognised adenomacarcinoma sequence in the
natural history of large bowel cancer suggests that this is a
malignancy likely to be susceptible to screening. Detection
and removal of precancerous adenomas and early invasive
carcinomas should lead to a reduction in incidence and mor-
tality respectively. Moreover the disease itself and the
methods of testing for it fulfil many of the criteria required
before implementation of a public health screening pro-
gramme (Wilson & Jungner, 1968).
Firstly, colorectal cancer is a major problem in most
developed countries. In the UK it is the third commonest
cause of death from malignant disease coming after lung
cancer in men and breast and lung cancer in women. The
number of colorectal cancer deaths in England and Wales in
1987 was 8,228 men and 8,825 women (OPCS, 1989).
Survival rates have improved slightly over recent decades,
5-year relative survival of all registered cases diagnosed in
1971 being 30% (OPCS, 1981) and of cases registered in
1979-1981 being 35% (OPCS, 1986). Nevertheless, recent
advances in treatment have had less success in improving
survival than they have in improving patient comfort, and
the principal determinant of survival remains the stage of the
tumour at presentation. Survival rates of patients with
tumours diagnosed at Dukes' stage A are 80% or more,
falling to 20% or less for those diagnosed at Dukes' stage C
or who already have metastases. Unfortunately in normal
clinical practice less than 10% of patients present with stage
A disease (Stower & Hardcastle, 1985).
Another criterion for screening is that the natural history
of the disease should be understood. This requirement is not
fully met in the case of colorectal cancer or, for that matter,
for any other malignant disease. Nevertheless it is known
that at least some carcinomas of the large bowel develop
within polypoid adenomas, and that increasing size of
adenomas and a villous, as opposed to tubular, histology
indicate increasing likelihood of malignancy (Morson, 1976).
This implies a progression of epithelial changes of increasing
severity over time. The great majority of adenomas, however,
do not progress to malignancy, as shown by the prevalence
of adenomas found at autopsy of people who died from
other causes. One study (Vatn & Stalsberg, 1982) estimated
that the autopsy prevalence of large bowel adenomas was ten
times higher than the cumulative lifetime incidence of colo-
rectal cancer. Little is known about the distribution of time
from onset of adenoma to invasion in those adenomas that
do progress. In a recent series of patients who developed
carcinoma having previously had an untreated polyp, the
cumulative risk ofprogression to cancer was 2.5% at 5 years,
8% at 10 years and 24% at 20 years (Stryker et al., 1987).
Recent evidence on the molecular genetics of colorectal
cancer also supports the adenomacarcinoma sequence, since
mutation of the ras oncogene occurs in premalignant
adenomas as well as colorectal carcinomas; it has been sug-
gested that two later events in carcinogenesis, recessive
changes on chromosomes 5 and 18, mark the transition from
adenoma to carcinoma (Kerr, 1989).
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In summary, the natural history suggests that detection
and removal of adenomas may prevent some invasive cancers
although most of those detected would be non-progressive;
and detection and removal of stage A cancers may prevent
some deaths. There is insufficient knowledge of the distribu-
tion of the duration of the pre-invasive phase or the stage A
phase to decide an appropriate interval between repeated
screens.
Who should be screened? The clearest risk factor for colo-
rectal cancer is age. Both incidence (OPCS, 1988) and mor-
tality, (OPCS, 1989) rise steeply with increasing age; 94% of
cases and 96% of deaths occur among people aged over 50.
Family history is the only other risk factor currently
identifiable in the general population, but is not nearly sen-
sitive enough for population screening because the great
majority of tumours occur in people with no affected
relatives.
At young ages, however, a history of familial polyposis
coli or similar inherited syndromes, is an indication for
screening. Follow-up of such families is more akin to clinical
management of patients than population screening and it will
not be considered further here.
Three principal tests have been used to screen for colorec-
tal neoplasia, digital rectal examination, sigmoidoscopy and
faecal occult blood. Digital examination is an easy test
included as a routine part of clinical examination of a person
with gastrointestinal symptoms. But it is of minimal value for
screening since less than 10% of colorectal tumours are
within range of the examining finger (Winawer et al., 1985).
Sigmoidoscopy has been widely practised as a screening test
in the USA (e.g. Gilbertson, 1974). But this too is clearly
limited by the range of the instrument, the rigid sigmoido-
scope only reaching the distal 15-20 cm of the bowel and the
flexible fibreoptic sigmoidoscope reaching up to 60cm. The
latter range includes the whole rectosigmoid region in which
50% of colorectal neoplasia occurs. It seems to be assumed
that sigmoidoscopy is 100% sensitive for detecting tumours
in its range (no false negatives), and also 100% specific (no
false positives). Its acceptability to a general population is
unknown because its use in the US has been among
volunteers.
Recently much more research has been done on the use of
faecal occult blood tests (UKCCCR, 1989), and their value
has been comprehensively reviewed by an EC/ESO Advisory
Group (Hardcastle et al., 1990). The qualitative tests, which
may be chemical or immunological are quick, easy and cheap
to perform. In some test kits, e.g. Haemoccult, the person
being screened places a small stool sample on a guaiac-
impregnated card and sends it off to be tested; in others, e.g.
Coloscreen, he performs and interprets the test himself, by
observing colour change.
Unlike sigmoidoscopy, faecal occult blood tests can detect
blood from any part of the bowel but, because haemoglobin
is degraded as it passes through the gastrointestinal tract,
they are less sensitive for upper gastrointestinal lesions than
for lower. They are also less sensitive for rectal lesions than
for higher left-sided lesions possibly because there has been
less opportunity for blood to be diffused widely through the
whole stool. Blood loss from colorectal cancers is variable
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from day to day (Doran & Hardcastle, 1982), and therefore
the usual, if arbitrary, recommendation is that three or six
successive stool specimens should be screened. Adenoma
detection is related to the size of the adenoma (Macrae & St
John, 1982). Test sensitivity is also inversely related to the
dryness of the stool sample when tested and some authorities
recommend rehydration.
There is also a problem with false positives in faecal occult
blood testing. Red meat and peroxidase-containing
vegetables such as tomatoes may give false positive results to
the chemical tests and therefore dietary restriction for three
days before the test is sometimes recommended. Immuno-
logical tests are specific to human haemoglobin but detect
levels within the range of normal blood loss, thus leading to
many false positives. Thus faecal occult blood tests for use in
screening need to balance their level of sensitivity for detec-
tion of haemoglobin against the requirement to keep false
positives as low as possible.
Sensitivity of screening in the epidemiological sense de-
scribes the test's ability to pick up all the neoplasia detectable
at that time plus that which is likely to arise to a sympto-
matic stage in the interval before the next routine screen.
Cancers presenting symptomatically after a negative screen
are known as interval cases. Sensitivity may be expressed as
the proportion of cancers which are screen-detected out of
the sum of screen-detected and interval cancers. Using this
definition and a two year interval, the sensitivity of Haem-
occult screening in a large population based study in
Nottingham was 75% (Hardcastle et al., 1989). An alterna-
tive definition expresses sensitivity as the proportion of
cancers whose diagnosis was advanced by screening out of all
those expected in the interval after screening. The expected
incidence can be derived from that in a control group. The
same study calculated sensitivity by this method to be 65%.
The sensitivity for adenoma detection is unknown.
Specificity means the test's ability to discard all people
without neoplasia, and in the Nottingham study was 99%.
The predictive value of a positive screening test in Notting-
ham was 58%, in Funen, Denmark was 57% (Kronborg et
al., 1989) and in Dijon, France was 44% (Bedenne et al.,
1990).
Another major determinant of the success of any screening
programme is its acceptance by the target population. Nic-
holls et al. (1986) compared different methods of invitation
to do a Haemoccult test and found that acceptance was
greatest (57%) among people offered the test during a con-
sultation with their general practitioner, but was only 38%
when the test was sent by post. Inclusion of an educational
leaflet made no difference, a fact also confirmed in Notting-
ham (Pye et al., 1988). In Dijon, administration of the test by
a doctor also achieved higher response (57%) than when it
was mailed (40%). Acceptance of a posted Haemoccult test
in the Nottingham study (Hardcastle et al., 1989) has been
53% with a slight variation with age and sex (greatest among
men aged 55-69 and women 50-69), but higher rates of
65% have been found in Scandinavian countries (Kronborg
et al., 1987; Kewenter et al., 1988). The factors influencing
compliance were studied by Farrands et al. (1984), who
found that acceptors of screening had much more positive
attitudes towards preventive medicine and were more opti-
mistic about health than non-attenders. This emphasises the
need for education targetted on people with negative fatalis-
tic views about prevention, for otherwise they will continue
to decline screening and present later with advanced disease,
thus lessening the potential of the screening programme to
achieve its objective.
From the foregoing it is clear that screening for colorectal
cancer by faecal occult blood is feasible, having tolerable
levels of acceptance, sensitivity and specificity. But what of
its effectiveness?
All of the research so far, concludes that screening can
meet the initial requirements for success, namely an increased
prevalence of cancer and adenomas at the first screen, and a
shift towards an earlier stage distribution. The Nottingham
study found a prevalence of cancer three times greater than
the annual incidence in the control group and a prevalence of
adenoma 40 times greater. Moreover the proportion of stage
A cancers in all recent studies is over 50%, and in two
(Gilbertsen, 1974; Kronborg et al., 1989) the survival of
screen-detected cases is shown to be greater than that of a
control population. But, although changes in prevalence,
stage distribution and survival are necessary findings if
screening is to succeed, they are insufficient proof that screen-
ing saves lives (Chamberlain, 1988). A reduction in the death
rate from colorectal cancer in the whole target population is
the only valid way of proving benefit from screening for
cancer - or a reduction in incidence of invasive cancer in the
case of screening for premalignant adenomas. Retrospective
correlation of death rates with screening intensity is some-
times possible. In West Germany where screening has been
available for people over 45 for many years mortality rates
have fallen by nearly 20% in the past 10 years but there is
insufficient information on screening intensity to draw any
firm conclusion on cause and effect (Robra, personal com-
munication). A case-control study to compare the screening
history of people who have died of colorectal cancer and
matched living controls is in progress.
A preferable form of evaluation is a prospective ran-
domised controlled trial and several of these are under way.
The earliest was a trial of a multiphasic health check-up in
which sigmoidoscopy was one of the tests offered. After 11
years this study reported a statistically significant reduction
of 70% in colorectal cancer mortality among the study group
who had been invited to be screened, but closer examination
of the data revealed a number of reasons why the lower
mortality could not be attributed to screening (Selby et al.,
1988).
A trial of faecal occult blood screening has been in pro-
gress in Minnesota for the past 11 years. A report in 1987
showed no difference in overall gastrointestinal cancer mor-
tality (Mandel et al., 1987) between the population offered
screening and the control population, but no data are yet
available on colorectal cancer mortality. This study enrolled
only 30,000 subjects aged 50-79 into the study group and
15,000 into the control group, and most were volunteers;
both the small sample size and the self-selected population
suggest that the number of colorectal cancer deaths among
the control group will be too small to be able to demonstrate
a statistically significant difference without many years of
follow-up.
In Denmark a trial involving 31,000 subjects in each group
has reported a deficit of deaths in the group offered screening
(37 deaths) compared with the control groups (51 deaths) but
this is not statistically significant and, again, many years of
further follow-up will be required (Kronborg et al., 1989).
The Nottingham trial calculated that 56,000, subsequently
revised to 78,000, subjects were required in each group to be
80% certain of showing a statistically significant difference of
20% or more between colorectal cancer mortality in study
and control groups after a minimum follow-up of 7 years
(Moss et al., 1987). The Swedish controlled trial (Kewenter et
al., 1988) has a small sample of 13,750 subjects aged 60-64
at entry, in each group, which, even with long follow-up, will
probably only be capable of showing a difference if it is
dramatically large.
So far only one study (Gilbertson & Nelms, 1978) has
reported the effect of adenoma removal on subsequent inci-
dence. Screening in this study was by rigid sigmoidoscopy
and 40 rectal cancers were found over a 5-year period,
compared to an expectation of 90 cancers. However, Miller
(1987) has cast doubt on the way in which the number of
expected cancers was calculated suggesting that a figure of 38
is nearer the truth. Hence the effect of adenoma removal on
subsequent cancer incidence also remains unproven.
In summary, the large amount of research into screening
for colorectal cancer has shown that it is feasible and that its
early findings are reasonably optimistic. However, inform-
ation about its effects on reducing mortality and incidence is
still lacking and it cannot be recommended other than on an
research basis. It is probably unnecessary to set up any moreSCREENING FOR COLORECTAL CANCER 3
randomised controlled trials but further research priorities
include trials of methods of improving compliance, develop-
ing screening tests of greater sensitivity without loss of
specificity, and investigating the costs as well as the benefits
of this public health programme.
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